Library / Laws / 117th Congress / House Bills / H.R. 153
H.R. 153
To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
| Print stage | Date | Size | ⠃ |
|---|---|---|---|
| Introduced in House | 2021-01-04 | 19.1K | ⠃⠗⠋ |